Ads
related to: opdivo- Dosing & Administration
Get Recommended
Dosing
- Peer Videos
Watch Videos Sharing
Clinical And Patient Experiences
- Mechanism Of Action
Details About Therapy
MOA
- Clinical Trial Results
Review Data From
3 Clinical Studies
- Patient Support
Complete Patient Support
And Product Information
- Request A Rep
Contact A Representative To
Learn More About This Product
- Dosing & Administration
Search results
Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
Zacks via Yahoo Finance· 3 hours agoBristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the...
BMS secures another EC approval for Opdivo combination
Pharmaceutical Technology via Yahoo Finance· 1 day agoThe European Commission (EC) has granted Bristol Myers Squibb (BMS) approval for its Opdivo...
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
Barrons.com· 6 days agoThe American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual...
Transcenta’s Osemitamab succeeds in Phase IIa G/GEJ cancer triple combo trial
Clinical Trials Arena via Yahoo Finance· 2 days agoThe TranStar102 study (NCT04495296) investigated osemitamab in combination with Opdivo (nivolumab)...
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults
WROC Rochester· 2 days agoUSA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years...
Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
Zacks via Yahoo Finance· 6 days agoIovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its...
Pipeline Moves: Phase III AML trial fails to meet primary endpoint
Clinical Trials Arena via Yahoo Finance· 2 days agoThe Phase I/II study planned to test the safety and tolerability of BMS-986218 as a monotherapy and...
BostonGene Immune Profiling Platform Shows Promise in Predicting Cancer Immunotherapy Benefit
GenomeWeb News· 6 days agoBostonGene wants to further validate a blood-based, machine learning-powered immune profiling platform that has shown potential in classifying cancer patients' immune phenotypes and monitoring ...
Bristol-Myers Squibb (NYSE:BMY) Shares Down 1.1%
ETF DAILY NEWS· 5 days agoShares of Bristol-Myers Squibb (NYSE:BMY – Get Free Report) fell 1.1% during trading on Thursday . The company traded as low as $41.58 and last traded at $41.89. 3,501,801 shares changed hands ...
Q2 2025 Earnings Estimate for Bristol-Myers Squibb Issued By Zacks Research (NYSE:BMY)
ETF DAILY NEWS· 3 days agoBristol-Myers Squibb (NYSE:BMY – Free Report) – Investment analysts at Zacks Research raised their Q2 2025 earnings estimates for shares of Bristol-Myers Squibb in a research report issued on ...